Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Last trade$0.6101
Day change-$0.0329 (-5.12%)
Day range$0.551 – $0.633
Volume753,303
Market cap$40M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$40.3M
Price / earnings
—
Price / book
1.5×
Price / sales
13.65×
EV / sales
4.5×
EV / EBITDA
-0.19×
Profitability
Earnings per share
-$1.10
Return on assets
-159.37%
Return on equity
-257.93%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.37×
Quick ratio
2.37×
Cash ratio
1.66×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$60.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CNTB, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$2.77M
$169K
$0
$16K
$48K
$0
$698K
$1.22M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$2.77M
$169K
$0
$16K
$48K
$0
$698K
$1.22M
Selling, general and administrative
$4.1M
$4.75M
$4.24M
$6.58M
$4.7M
$4.81M
$4.08M
$6.06M
Research and development
$16.27M
$15.03M
$11.28M
$11.11M
$8.77M
$6.63M
$6.24M
$9.01M
Total operating expenses
$20.37M
$19.78M
$15.53M
$17.69M
$13.47M
$11.45M
$10.32M
$15.07M
Operating income
-$17.6M
-$19.61M
-$15.53M
-$17.68M
-$13.42M
-$11.45M
-$9.62M
-$13.85M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$17.22M
-$19.35M
-$15.08M
-$17.14M
-$12.84M
-$10.22M
-$8.8M
-$12.82M
Income taxes
$60K
$48K
$27K
$61K
$55K
$54K
$106K
$57K
Net income
-$17.28M
-$19.4M
-$15.11M
-$17.2M
-$12.9M
-$10.27M
-$8.91M
-$12.88M
Net income attributable to common shareholders
-$17.28M
-$19.4M
-$15.5M
-$17.1M
-$12.9M
-$10.27M
-$9.33M
-$12.31M
EBITDA
-$17.44M
-$19.44M
-$15.35M
-$17.5M
-$13.25M
-$11.27M
-$9.46M
-$13.67M
Basic earnings per share
-$0.27
-$0.34
-$0.28
-$0.31
-$0.23
-$0.19
-$0.17
-$0.23
Diluted earnings per share
-$0.27
-$0.34
-$0.28
-$0.31
-$0.23
-$0.19
-$0.17
-$0.23
Recent news
Company coverage with links to the original publishers.
Connect Biopharma Holdings (CNTB) stock has declined 29.2% over the past four weeks but formed a hammer chart pattern in its last trading session, suggesting potential support and trend reversal. Rising analyst optimism about future earnings and a Zacks Rank #2 (Buy) rating support the possibility of a turnaround.
Connect Biopharma reported Q1 2026 financial results and provided updates on its Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD. The independent Data Monitoring Committee confirmed no safety concerns and adequate study power, with topline data expected mid-2026. The company closed a $20.2 million private placement and has $46 million in cash, sufficient to fund operations into H2 2027. Positive Phase 1 IV rademikibart data showed rapid lung function improvements within 15 minutes.
Connect Biopharma will present two poster presentations at the ERS Congress 2025 about rademikibart, a monoclonal antibody targeting IL-4Rα for treating asthma and inflammatory diseases.
Connect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.
Connect Biopharma will present at the BTIG Virtual Biotechnology Conference on July 29th, 2025, discussing their clinical-stage development of rademikibart, an antibody targeting IL-4Rα for treating asthma and COPD.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.